Results 201 to 210 of about 111,862 (289)

BRCA1 and BRCA2 pathogenic variants increase the risk of four less common cancer types. [PDF]

ESMO Open
Sasagawa H, Endo M, Iwasaki Y, Usui Y, Koyanagi YN, Innella G, Hadler J, Parsons MT, Numakura K, Kamatani Y, Murakami Y, Matsuo K, Matsuda K, Spurdle AB, Habuchi T, Momozawa Y.   +15 more
europepmc   +1 more source

Targeting PRMTs Creates Vulnerability of DNA Double‐Stand Break Repair Pathways, and Potentiates Chemotherapy Efficacy in TNBC

Cancer Science, Volume 117, Issue 5, Page 1273-1285, May 2026.
Our work makes the proof of concept that there is a clinical benefit to target both PRMT1 and PRMT5 to maximize the anti‐tumoral effect of chemotherapy in triple negative breast cancer. ABSTRACT Patients with triple‐negative breast cancer (ER−, PR−, and HER2−) are routinely treated with chemotherapies that induce DNA damage.
Charlène Thiebaut, Sébastien Martinez, Ludivine Pruvost, Louisane Eve, Rania El‐Botty, Laura Sourd, Elodie Montaudon, Ahmed Dahmani, Heloise Derrien, Stéphanie Sentis, Coralie Poulard, Elisabetta Marangoni, Olivier Trédan, Muriel Le Romancer   +13 more
wiley   +1 more source

A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2. [PDF]

Clin Cancer Res
Huffman BM, Diossy M, Yurgelun MB, Horick N, Li YY, Crowdis J, Nguyen H, Parmar K, Kochupurakkal BS, Vonk L, Lam H, Ramsey K, Andrews E, Loeb SC, Culnane L, Biller LH, Bullock AJ, Enzinger A, Giannakis M, Jackson NA, Ng K, Nowak JA, Patel AK, Perez KJ, Rattani A, Rubinson DA, Schlechter BL, Singh H, Cai M, Raghavan S, Clark JW, Peters ML, Weipert CM, Wolpin BM, D'Andrea AD, Shapiro GI, Aguirre AJ, Szallasi Z, Cleary JM.   +38 more
europepmc   +1 more source

Early‐Onset Digestive System Cancers: Risk Factors and Clinicopathological and Molecular Features Across Organ Sites

Cancer Science, Volume 117, Issue 5, Page 1223-1234, May 2026.
Shared risk factors, clinical features, and tumor characteristics across multiple early‐onset cancer types are shown in this Graphical Abstract. Integrative approaches combining molecular pathology, oncology, and population sciences offer opportunities to clarify underlying mechanisms and help us develop preventive strategies for early‐onset cancers ...
Nobuhiro Nakazawa, Satoko Ugai, Atsushi Kondo, Kosuke Matsuda, Shu Kato, Genki Usui, Shiori Tanaka, Hwa‐Young Lee, Xinyuan Zhang, Hideo Miyagawa, Mai Chan Lau, Hiroshi Saeki, Yukihide Kanemitsu, Andrew T. Chan, Shuji Ogino, Minkyo Song, Juha P. Väyrynen, Tomotaka Ugai   +17 more
wiley   +1 more source

The mitochondrial translocation of phosphorylated EZH2 promotes PARP inhibitor resistance in BRCA1-deficient epithelial ovarian cancer. [PDF]

Cell Discov
Hu L, Ma X, Cai X, Yan T, Zhou K, Shan C, Guo N, Zheng H, Wang Y, Tong Y, Xie S, Zhang H, Chen C, Gong Z, Guo L, Lu R.   +15 more
europepmc   +1 more source

Genomic Profiling in Localized Prostate Cancer: Associations With Biochemical Recurrence and Response to Salvage Radiotherapy

Cancer Science, Volume 117, Issue 5, Page 1469-1480, May 2026.
Early screening for somatic alterations in localized prostate cancer could help predict biochemical recurrence risk and optimize salvage therapy selection. ABSTRACT The clinical significance of comprehensive genomic profiling (CGP) has been established in metastatic castration‐resistant prostate cancer (PC).
Kenji Zennami, Tetsuya Takimoto, Takuhisa Nukaya, Makoto Sumitomo, Mayu Takeda, Eiji Sugihara, Hideyuki Saya, Ryoichi Shiroki   +7 more
wiley   +1 more source

An Inducible BRCA1 Expression System with In Vivo Applicability Uncovers Activity of the Combination of ATR and PARP Inhibitors to Overcome Therapy Resistance. [PDF]

Cancers (Basel)
Irving E, Morcavallo A, Vohhodina-Tretjakova J, Wijnhoven PWG, Beckett AL, Jacques MP, Evans RS, Moss JI, Staniszewska AD, Forment JV.   +9 more
europepmc   +1 more source

Cancer Biomarker Test Utilization and Reimbursement in Australia: A National Analysis of Medicare Data

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Biomarker testing plays a critical role in precision oncology by guiding targeted therapy selection. In Australia, public reimbursement for somatic tumor biomarker tests has expanded over the past decade, yet national data on utilization patterns, equity of access, and public expenditure remain limited. We identified all cancer biomarker tests
Leping Kong, Christine Y. Lu
wiley   +1 more source

Evaluating the Impact of Putative Metformin Targets on Cancer Outcomes: A Drug‐Target Mendelian Randomization Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4091-4099, May 2026.
ABSTRACT Aims Observational studies show metformin use associated with lower cancer risk, although experimental evidence is inconsistent. To provide genetic validation for repositioning of metformin in cancer prevention, we assessed genetically proxied effects of putative metformin targets on cancer outcomes using a drug‐target Mendelian randomization (
Xingyu Shen, Shan Luo, Jie Zheng, Celine Sze Ling Chui, Ian Chi Kei Wong, Eric Yuk Fai Wan, Catherine Mary Schooling, Shiu Lun Au Yeung   +7 more
wiley   +1 more source

Rapid and sensitive detection of BRCA1/2 mutations in a diagnostic setting: Comparison of two high-resolution melting platforms [PDF]

, 2008
Claes, Kathleen, Coene, Ilse, De Leeneer, Kim, De Paepe, Anne, Poppe, Bruce   +4 more
core   +1 more source